OSI Pharmaceuticals, Inc.
OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Published in Oncology Business Week, December 6th, 2009
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced that the Oncologic Drugs Advisory Committee (ODAC) will review the use of Tarceva® (erlotinib) as a first-line maintenance therapy for patients with advanced non-small cell lung cancer (NSCLC) who have not progressed following first-line treatment with platinum-based chemotherapy at its December 16, 2009 meeting. The ODAC panel is a committee of external experts, formed by the U.S. Food and Drug Administration (FDA), to advise the FDA in the evaluation of marketed and investigational drugs for use in the treatment of cancer.
In June 2009, the FDA accepted for filing and review the supplemental New Drug Application...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
More Articles from Oncology Business Week
- 1-800-GOT-MOLD?
1-800-GOT-MOLD?'s Dog Detectives Have a Leg Up on the Competition - AARP Idaho
Survey Finds AARP Members Back Health Care Reform Legislation - AARP Illinois
Survey Finds Nearly 70 Percent of Illinois AARP Members Back Health Care Reform Legislation - AARP Pennsylvania
Survey Finds Pennsylvania AARP Members Back Critical Provisions of Health Care Reform Legislation - Aegera Therapeutics INC.
Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia AML - Aeolus Pharmaceuticals, Inc.
Duke University Initiates Study of AEOL 10150 to Measure Compound's Ability to Protect Healthy Tissue in Mice Receiving Chemotherapy and Radiation for Non-Small Cell Lung Cancer - More from this issue of Oncology Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
